Glucose-6-phosphate dehydrogenase (G6PD) (EC 1.1.1.49) is the enzyme that catalyses the first step of the pentose phosphate pathway and produces NADPH. NADPH is required for the generation of reduced glutathione, an agent that protects red blood cells from the toxic action of reactive oxygen species (ROS). G6PD deficiency is the most commonly inherited enzymopathy and is widely spread in Greece, with a mean prevalence of 3.1% and 6.3% in Northern Greece [1,2]. G6PD deficiency demonstrates an X-linked recessive pattern of inheritance and is associated with asymptomatic patients who may experience haemolysis under specific circumstances. G6PD Harilaou is a new variant that was first described in Greece in an eight-year-old boy who suffered chronic haemolysis demanding multiple transfusions. We present a new case of the G6PD Harilaou variant in a Greek male neonate who suffered severe intrauterine haemolysis and passed away 39 hours after birth. To our knowledge, it is the second reported G6PD Harilaou case.

Abstract

G6PD deficiency is one of the most commonly inherited enzymopathies with a hallmark of an X-linked pattern. G6PD has more than 300 unique variants with different enzyme activity. The G6PD Mediterranean variant is prevalent in Greece and associated with asymptomatic patients who may experience haemolysis under specific circumstances. G6PD Harilaou is a new variant that was first described in Greece in an eight-year-old boy who suffered chronic haemolysis demanding multiple transfusions. We present a new case of the G6PD Harilaou variant in a Greek male neonate who suffered severe intrauterine haemolysis and passed away 39 hours after birth. To our knowledge, it is the second reported G6PD Harilaou case.

Keywords

G6PD deficiency, meconium aspiration syndrome, G6PD Harilaou, intrauterine haemolysis

Received: 2020 December 17   Accepted: 2021 March 25
A male neonate was born to a G2P2 mother at 36 weeks of gestation with an emergency caesarean section due to an abnormal foetal nonstress test. According to Fenton preterm growth charts [7], the baby’s values were the following: birth weight [2870g (66th percentile)], length [49 cm (86th percentile)], and head circumference [34.5 cm (93rd percentile)]. During labour, the amniotic fluid was meconium stained. The neonate was severely compromised, experienced respiratory distress and required resuscitation with intubation in the delivery room. The Apgar score was 1’ [2], 5’ [4], and 10’ [5]. After stabilisation, the newborn was transferred to the NICU in critical condition. Meconium aspiration syndrome (MAS) was detected, along with persistent pulmonary hypertension and metabolic and respiratory acidosis (ABG: pH 6.81, pCO2 80.5 mmHg, HCO3- 9 mmol/L, pO2 30.2 mmHg, ABE -24 mmol/L, cLac 85 mg/dl). Due to severe respiratory insufficiency and an oxygenation index above 25, the newborn was directly subjected to high-frequency oscillatory ventilation (HFOV) and nitric oxide administration. The first settings on the HFOV device were the following: FiO2 100%, PIP 35 cmH2O, PEEP 6 cmH2O, BPM 60/min, IT 0.42 sec. In addition, the head ultrasound showed diffused cerebral oedema. Laboratory tests revealed persistent anaemia and failure to sustain a Ht of more than 22% despite three blood transfusions. The cord blood haemoglobin was 7 g/dl, and the reticulocyte count was 41%—findings that are consistent with haemolytic anaemia. The Coombs test was negative, excluding autoimmunity. There was no hydrops nor jaundice. It is essential to highlight that all previous laboratory exams and nonstress tests were normal, suggesting an uncomplicated pregnancy. A review of all findings showed that intrauterine haemolysis had occurred. The family history of the maternal uncle, who was the first reported G6PD Harilaou in intrauterine haemolysis had occurred. The family history of the maternal uncle, who was also tested.

Class I
Severe enzyme deficiency (<1% residual activity) chronic non-spherocytic haemolysis

Class II
Severe enzyme deficiency (1–10% residual activity) intermittent acute haemolysis

Class III
Moderate enzyme deficiency (10–60% residual activity) intermittent acute haemolysis

Class IV
No enzyme deficiency (60–150% activity)

Class V
Increased enzyme activity (>150%)

The case we demonstrate is the second reported case of a patient with the G6PD Harilaou variant. Remarkably, in our patient the mutation had a more profound clinical appearance. The Harilaou variant can be compared to the Guadalajara variant (Class I, WHO) [8], which manifested with haemolysis, foetal anaemia and jaundice. However, the baby of the published Guadalajara case had a favourable outcome. In our case, G6PD deficiency in the maternal uncle became clinically obvious at the age of three years with the manifestation of transfusion-refractory anaemia. However, he underwent a splenectomy and survived. Today he is about 38 years old and coping with chronic anaemia via periodic transfusions when required. Our patient’s clinical manifestations did not match the usual asymptomatic profile of the G6PD Mediterranean variant. The baby suffered intrauterine haemolysis, developing chronic haemolysis and hypoxia. MAS followed, as hypoxia and acidosis are strong stimulants for meconium passage in utero (a condition known as meconium-stained amniotic fluid (MSAF)), owing to vagal stimulation and anal sphincter relaxation. MSAF complicates almost 10–15% of childbirths, while MAS occurs in 5% of them [9]. MAS is a clinical syndrome defined by respiratory distress in a neonate born with MSAF, a need for oxygen to maintain SaO2 at 92% or more, oxygen requirements that start during the first two hours of life and that last for at least 12 hours, and the absence of congenital cardiac or pulmonary malformations [10]. The MSAF is aspirated from the foetus and fills the airways, leading to severe respiratory distress and pulmonary hypertension. MAS pathophysiology combines pulmonary dysfunction with a systemic inflammatory response. Persistent pulmonary hypertension, though, remains the leading cause of death in MAS, as happened in our case.

In the family pedigree (fig. 1), it is obvious that the newborn inherited the G6PD Harilaou variant from his mother, who was found to be a heterozygous carrier [11]. Thus, her sons inherited a normal and a Harilaou X-linked variant, respectively [12]. We conclude that the maternal grandmother was heterozygous for the Harilaou variant.
Conclusion

G6PD deficiency can be caused by several mutations, leading to a spectrum of mild, moderate or severe clinical presentation. Some of them can lead to life-threatening chronic haemolysis and neonatal death. Although the Mediterranean variant prevails in Greece, clinicians should always stay alert to detect carriers of variants with a more severe phenotype. This case highlights the need for intensified monitoring in women with a family history of this disorder in order to ensure the well-being of the foetus.

Bulleted key points
- This is the second published case of a patient with G6PD deficiency and Harilaou variant.
- G6PD Harilaou is a rare and potentially lethal variant that may cause intrauterine haemolysis.
- G6PD variants are related, with various enzyme activity and severity of haemolysis.
- Women with a family history of G6PD deficiency and haemolysis should be offered intensified foetal monitoring.

ORCID identifiers of the authors
Kleoniki I. Athanasiadou 0000-0002-0811-8156 (https://orcid.org/0000-0002-0811-8156)
Maria Amarantidou 0000-0001-9600-3203 (https://orcid.org/0000-0001-9600-3203)
Eftychia Drogouti 0000-0002-5327-9370 (https://orcid.org/0000-0002-5327-9370)
Marina Economou 0000-0002-6742-4348 (https://orcid.org/0000-0002-6742-4348)
George Mitsiakos 0000-0001-9796-1614 (https://orcid.org/0000-0001-9796-1614)
Evgenia Papakonstantinou 0000-0001-5620-7885 (https://orcid.org/0000-0001-5620-7885)
Paraskevi Karagianni 0000-0002-1862-9072 (https://orcid.org/0000-0002-1862-9072)

Funding acknowledgement
The authors declare that they had no funding source or specific support.

Statement of interest
The authors report no conflicts of interest.

Conflicts of interest
The authors declare that there is no conflict of interest.

Acknowledgements
There are none.

Author contributions
KIA and PK designed the manuscript and conceived the original idea. KIA and MA drafted the manuscript, and all authors contributed to its final form, and critically reviewed the manuscript.

References
1. Ntaios G, Chatzinikolaou A, Tomos C, Manolopoulos C, Karalazos P, Nikolaidou A, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in Northern Greece. Intern Med J. 2008;38(3):204-6. doi: 10.1111/j.1445-5994.2007.01618.x.
2. Missiou-Tsagaraki S. Screening for glucose-6-phosphate dehydrogenase deficiency as a preventive measure: prevalence among 1,286,000 Greek newborn infants. J Pediatr. 1991;119(2):293-9. doi: 10.1016/s0022-3476(05)80747-4.
3. Bulliamy T, Luzzatto L, Hiroto A, Beutler E. Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis. 1997;23(2):302-13. doi: 10.1016/s0022-3476(05)80747-4.
4. Vives-Corrons JL, Kuhl W, Pujades MA, Beutler E. Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A. Am J Hum Genet. 1990;47(3):575-9.
5. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-78. doi: 10.1016/j.bcmd.2008.12.005.
6. Town M, Athanasiou-Metaxa M, Luzzatto L. Intragenic interspecific complementation of glucose 6-phosphate dehydrogenase in human-hamster cell hybrids. Somat Cell Mol Genet. 1990;16(2):97-108. doi: 10.1007/BF01233040.

7. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13:59. doi: 10.1186/1471-2431-13-59.

8. Keller CC, Joosten M, Middeldorp AM, Knapen MF. Fetal anemia caused by the Guadalajara variant of G6PD deficiency. Prenat Diagn. 2015;35(12):1255-7. doi: 10.1002/pd.4677.

9. Choudhury SN, Kumar B, Saji PN. A Study of meconium aspiration syndrome and neonatal outcome: a prospective study. J Med Sci Clin Res. 2020;8(6):226-231. doi: 10.18535/jmscr/v8i6.41.

10. Lindenskov PH, Castellheim A, Saugstad OD, Mollnes TE. Meconium aspiration syndrome: possible pathophysiological mechanisms and future potential therapies. Neonatology. 2015;107(3):225-30. doi: 10.1159/000369373.

11. Poggi V, Town M, Foulkes NS, Luzzatto L. Identification of a single base change in a new human mutant glucose-6-phosphate dehydrogenase gene by polymerase-chain-reaction amplification of the entire coding region from genomic DNA. Biochem J. 1990;271(1):157-60. doi: 10.1042/bj2710157.

12. Davidson R, Nitowsky H, Childs B. Demonstration of two populations of cells in the human female heterozygous for glucose-6-phosphate dehydrogenase variants. Proc Natl Acad Sci U S A. 1963;50(3):481-5. doi: 10.1073/pnas.50.3.481.